The PALETTE randomized phase III trial has reported a statistically significant benefit for the use of pazopanib compared to placebo in terms of progression-free survival for the treatment of soft-tissue sarcoma. However, no benefit in terms of overall survival was observed, the reasons for which might lie in the study design.
Key Points
-
The PALETTE study was the first randomized phase III trial to demonstrate efficacy of an antiangiogenic agent in pretreated patients with soft-tissue sarcoma
-
The positive results and consistency across several disease subgroups confirm pazopanib as an option for patients with metastatic disease progression after chemotherapy
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mice null for the deubiquitinase USP18 spontaneously develop leiomyosarcomas
BMC Cancer Open Access 10 November 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Casali, P. G. & Blay, J. Y. on behalf of the ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21 (Suppl. 5), 198–203 (2010).
Le Cesne, A. et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23, 576–584 (2005).
Maki, R. G. et al. Randomised phase 2 study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Trough Collaboration Study 002. J. Clin. Oncol. 25, 2755–2763 (2007).
García-Del-Muro, X. et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J. Clin. Oncol. 29, 2528–2533 (2011).
Penel, N. et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J. Clin. Oncol. 26, 5269–5274 (2008).
Rutkowski, P., Kaminska, J., Kowalska, M., Ruka, W. & Steffen, J. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int. J. Cancer 100, 463–471 (2002).
Sleijfer, S. et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J. Clin. Oncol. 27, 3126–3132 (2009).
van der Graaf, W. T. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379, 1879–1986 (2012).
Mackey, J. et al. Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treat. Rev. 38, 673–688 (2012).
Pàez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220–231 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Ray-Coquard, I., Thomas, D. Pazopanib for soft-tissue sarcoma: a PALETTE of data emerges. Nat Rev Clin Oncol 9, 431–432 (2012). https://doi.org/10.1038/nrclinonc.2012.113
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.113
